论文部分内容阅读
[目的]观察冠心舒通胶囊联合缬沙坦治疗高血压左室肥厚心肌缺血疗效。[方法]使用随机平行对照方法,将80例住院患者按病志号抽签简单随机分两组。对照组40例缬沙坦,1次/d,1片/次,口服。治疗组40例冠心舒通胶囊,3粒/次,3次/d;缬沙坦治疗同对照组。连续治疗6个月为1疗程。观测临床症状、收缩压、舒张压、LVDPWT(左心室舒张末期后壁厚度)、IVST(左心室舒张末期间隔厚度)、LVDD(左心室舒张末期内径)、LVMI(左心室质量指数)、不良反应。治疗1疗程,判定疗效。[结果]治疗组显效17例,有效20例,无效3例,总有效率92.50%;对照组显效15例,有效15例,无效10例,总有效率75.00%;治疗组疗效优于对照组(P<0.05)。收缩压、舒张压、LVDPWT、IVST、LVDD、LVMI两组均有改善(P<0.05),治疗组改善优于对照组(P<0.05)。[结论]冠心舒通胶囊联合缬沙坦治疗高血压左室肥厚心肌缺血,疗效满意,无严重不良反应,值得推广。
[Objective] To observe the curative effect of Guanxin Shutong Capsule combined with Valsartan on hypertensive left ventricular hypertrophy myocardial ischemia. [Methods] Using randomized parallel control method, 80 inpatients were randomly divided into two groups randomly according to the patient’s lot number. Control group, 40 cases of valsartan, 1 / d, 1 / time, orally. Treatment group, 40 cases of coronary heart Shu Tong capsule, 3 capsules / time, 3 times / d; valsartan treatment with the control group. Continuous treatment of 6 months for a course of treatment. Clinical symptoms, systolic blood pressure, diastolic blood pressure, LVDPWT (left ventricular end-diastolic wall thickness), IVST (left ventricular end diastolic septum thickness), LVDD (left ventricular end-diastolic diameter), LVMI . Treatment of a course of treatment to determine the efficacy. [Results] In the treatment group, 17 cases were markedly effective, 20 cases were effective, 3 cases were ineffective, and the total effective rate was 92.50%. In the control group, 15 cases were markedly effective, 15 cases were effective, 10 cases were ineffective and the total effective rate was 75.00% (P <0.05). Systolic blood pressure, diastolic blood pressure, LVDPWT, IVST, LVDD, LVMI improved in both groups (P <0.05), and the treatment group improved better than the control group (P <0.05). [Conclusion] Guanxinshutong capsule combined with valsartan in treatment of hypertensive left ventricular hypertrophy myocardial ischemia, satisfactory results, no serious adverse reactions, it is worth promoting.